Super enhancers define regulatory subtypes and cell identity in neuroblastoma / Moritz Gartlgruber, Ashwini Kumar Sharma, Andrés Quintero, Daniel Dreidax, Selina Jansky, Young-Gyu Park, Sina Kreth, Johanna Meder, Daria Doncevic, Paul Saary, Umut H. Toprak, Naveed Ishaque, Elena Afanasyeva, Elisa Wecht, Jan Koster, Rogier Versteeg, Thomas G.P. Grünewald, David T. W. Jones, Stefan M. Pfister, Kai-Oliver Henrich, Johan van Nes, Carl Herrmann, Frank Westermann
Half of the children diagnosed with neuroblastoma (NB) have high-risk disease, disproportionately contributing to overall childhood cancer-related deaths. In addition to recurrent gene mutations, there is increasing evidence supporting the role of epigenetic deregulation in disease pathogenesis. Yet, comprehensive cis-regulatory network descriptions from NB are lacking. Here, using genome-wide H3K27ac profiles across 60 NBs, covering the different clinical and molecular subtypes, we identified four major super-enhancer-driven epigenetic subtypes and their underlying master regulatory networks..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
---|---|
Enthalten in: |
Nature cancer - 2(2021), 1, Seite 114-128 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gartlgruber, Moritz [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Published: 07 December 2020 Gesehen am 08.12.2020 |
---|
Umfang: |
15 |
---|
doi: |
10.1038/s43018-020-00145-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1742231756 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | 1742231756 | ||
003 | DE-627 | ||
005 | 20240229114229.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201208s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s43018-020-00145-w |2 doi | |
035 | |a (DE-627)1742231756 | ||
035 | |a (DE-599)KXP1742231756 | ||
035 | |a (OCoLC)1341383264 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Gartlgruber, Moritz |e verfasserin |0 (DE-588)1170265197 |0 (DE-627)1038157900 |0 (DE-576)512463425 |4 aut | |
245 | 1 | 0 | |a Super enhancers define regulatory subtypes and cell identity in neuroblastoma |c Moritz Gartlgruber, Ashwini Kumar Sharma, Andrés Quintero, Daniel Dreidax, Selina Jansky, Young-Gyu Park, Sina Kreth, Johanna Meder, Daria Doncevic, Paul Saary, Umut H. Toprak, Naveed Ishaque, Elena Afanasyeva, Elisa Wecht, Jan Koster, Rogier Versteeg, Thomas G.P. Grünewald, David T. W. Jones, Stefan M. Pfister, Kai-Oliver Henrich, Johan van Nes, Carl Herrmann, Frank Westermann |
264 | 1 | |c 2021 | |
300 | |a 15 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Published: 07 December 2020 | ||
500 | |a Gesehen am 08.12.2020 | ||
520 | |a Half of the children diagnosed with neuroblastoma (NB) have high-risk disease, disproportionately contributing to overall childhood cancer-related deaths. In addition to recurrent gene mutations, there is increasing evidence supporting the role of epigenetic deregulation in disease pathogenesis. Yet, comprehensive cis-regulatory network descriptions from NB are lacking. Here, using genome-wide H3K27ac profiles across 60 NBs, covering the different clinical and molecular subtypes, we identified four major super-enhancer-driven epigenetic subtypes and their underlying master regulatory networks. | ||
700 | 1 | |a Sharma, Ashwini Kumar |e verfasserin |0 (DE-588)1099990297 |0 (DE-627)858934604 |0 (DE-576)46944200X |4 aut | |
700 | 1 | |a Quintero, Andrés |d 1988- |e verfasserin |0 (DE-588)1179394313 |0 (DE-627)1067073671 |0 (DE-576)518208257 |4 aut | |
700 | 1 | |a Dreidax, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Jansky, Selina |e verfasserin |4 aut | |
700 | 1 | |a Park, Young-Gyu |e verfasserin |4 aut | |
700 | 1 | |a Kreth, Sina |e verfasserin |4 aut | |
700 | 1 | |a Meder, Johanna |e verfasserin |4 aut | |
700 | 1 | |a Doncevic, Daria |e verfasserin |0 (DE-588)1222980657 |0 (DE-627)1742234496 |4 aut | |
700 | 1 | |a Saary, Paul |e verfasserin |0 (DE-588)1160321493 |0 (DE-627)1023464721 |0 (DE-576)505842092 |4 aut | |
700 | 1 | |a Toprak, Umut H. |e verfasserin |4 aut | |
700 | 1 | |a Ishaque, Naveed |e verfasserin |4 aut | |
700 | 1 | |a Afanasyeva, Elena |e verfasserin |4 aut | |
700 | 1 | |a Wecht, Elisa |e verfasserin |4 aut | |
700 | 1 | |a Koster, Jan |e verfasserin |4 aut | |
700 | 1 | |a Versteeg, Rogier |e verfasserin |4 aut | |
700 | 1 | |a Grünewald, Thomas G. P. |d 1980- |e verfasserin |0 (DE-588)13673426X |0 (DE-627)585870365 |0 (DE-576)301246432 |4 aut | |
700 | 1 | |a Jones, David T. W. |e verfasserin |0 (DE-588)1058669672 |0 (DE-627)79739334X |0 (DE-576)414823583 |4 aut | |
700 | 1 | |a Pfister, Stefan |d 1974- |e verfasserin |0 (DE-588)123850215 |0 (DE-627)706450930 |0 (DE-576)293908400 |4 aut | |
700 | 1 | |a Henrich, Kai-Oliver |d 1972- |e verfasserin |0 (DE-588)13029523X |0 (DE-627)497647303 |0 (DE-576)298111438 |4 aut | |
700 | 1 | |a van Nes, Johan |e verfasserin |4 aut | |
700 | 1 | |a Herrmann, Carl |d 1971- |e verfasserin |0 (DE-588)1081750952 |0 (DE-627)846593858 |0 (DE-576)454763409 |4 aut | |
700 | 1 | |a Westermann, Frank |d 1968- |e verfasserin |0 (DE-588)118119990 |0 (DE-627)69468628X |0 (DE-576)291725570 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature cancer |d London : Nature Research, 2020 |g 2(2021), 1, Seite 114-128 |h Online-Ressource |w (DE-627)1687330697 |w (DE-600)3005299-3 |x 2662-1347 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2021 |g number:1 |g pages:114-128 |g extent:15 |
856 | 4 | 0 | |u https://doi.org/10.1038/s43018-020-00145-w |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u https://www.nature.com/articles/s43018-020-00145-w |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 2 |j 2021 |e 1 |h 114-128 |g 15 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3819102000 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-12-20 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2021 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_23 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_15 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1551596768 |a Sharma, Ashwini Kumar | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416734031 |a BIOQUANT | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_2 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1588210340 |a Quintero, Andrés | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_3 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1742234763 |a Doncevic, Daria | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416535624 |a Institut für Pharmazie und Molekulare Biotechnologie (IPMB) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_9 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1742238017 |a Saary, Paul | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416822720 |a Extern | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_10 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1727464192 |a Grünewald, Thomas G. P. | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416741658 |a Pathologisches Institut | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_17 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1484823737 |a Jones, David T. W. | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_18 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s p |0 (DE-627)1464593051 |a Pfister, Stefan | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s k |0 (DE-627)1416740988 |a Zentrum für Kinder- und Jugendmedizin | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |a pos_19 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s p |0 (DE-627)1698662440 |a Henrich, Kai-Oliver | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 11 |s s |a pos_20 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s p |0 (DE-627)1524763446 |a Herrmann, Carl | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s k |0 (DE-627)1416535624 |a Institut für Pharmazie und Molekulare Biotechnologie (IPMB) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 12 |s s |a pos_22 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 13 |s p |0 (DE-627)1437388612 |a Westermann, Frank | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 13 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 13 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 13 |s s |a pos_23 |